<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544348</url>
  </required_header>
  <id_info>
    <org_study_id>CD-RI-MEDI4212-1085</org_study_id>
    <nct_id>NCT01544348</nct_id>
  </id_info>
  <brief_title>A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE &gt;= 30 IU/mL</brief_title>
  <official_title>A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE &gt;= 30 IU/mL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study to evaluate the safety of MEDI4212.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, randomized, placebo-controlled, dose-escalation study to evaluate the safety and
      tolerability of ascending single subcutaneous and intravenous doses of MEDI4212 in subjects
      with immunoglobulin E (IgE) greater than or equal to (&gt;=) 30 international units per
      milliliters (IU/mL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Day 1 to 85</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to Day 85 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed Serum Concentration</measure>
    <time_frame>Pre-dose and post-dose on Day 1; Day 2, 3, 5, 8, 15, 22, 29, 43, 57 and 85</time_frame>
    <description>Serum concentration of omalizumab and MEDI4212 were measured for participants who received omalizumab and MEDI4212, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Exhibiting Anti-Drug Antibodies for MEDI4212 at Any Visit</measure>
    <time_frame>Days 1 (pre-dose), 15, 43, and 85</time_frame>
    <description>Anti-drug antibodies for MEDI4212 were analyzed for participants who received placebo or MEDI4212 as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Immunoglobulin E (IgE) Serum Concentration</measure>
    <time_frame>Day -28 (Screening), -1, 1 (pre-dose), 2, 3, 5, 8, 15, 22, 29, 43, 57, and 85 for all groups; 2 hours post-dose on Day 1 for MEDI4212 300 mg Intravenous group only</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Allergic Asthma</condition>
  <condition>Atopic Dermatitis</condition>
  <condition>Allergic Rhinitis</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4212 5 mg Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4212 15 mg Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4212 60 mg Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4212 150 mg Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4212 300 mg Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4212 300 mg Intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
    <arm_group_label>Omalizumab</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4212 5 mg Subcutaneous</intervention_name>
    <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
    <arm_group_label>MEDI4212 5 mg Subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4212 15 mg Subcutaneous</intervention_name>
    <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
    <arm_group_label>MEDI4212 15 mg Subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4212 60 mg Subcutaneous</intervention_name>
    <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
    <arm_group_label>MEDI4212 60 mg Subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4212 150 mg Subcutaneous</intervention_name>
    <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
    <arm_group_label>MEDI4212 150 mg Subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4212 300 mg Subcutaneous</intervention_name>
    <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
    <arm_group_label>MEDI4212 300 mg Subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4212 300 mg Intravenous</intervention_name>
    <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
    <arm_group_label>MEDI4212 300 mg Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 60 years

          -  Written informed consent and any locally required authorization

          -  Body weight 45-150 kilogram (kg) for Cohorts 1-3, 4b, and 5-9. Body weight 45-90 kg
             for Cohort 4a

          -  Females must have been surgically sterilized or postmenopausal

          -  Non-sterilized males who are sexually active with a female partner of childbearing
             potential must use a highly effective method of contraception from Day 1 through Day
             85; Both partners to use contraception

          -  Sterilized males must be at least 1-year post vasectomy or use a highly effective
             contraceptive method

          -  Healthy Japanese population as determined by a responsible physician

          -  Current diagnosis of allergic rhinitis, allergic asthma, or atopic dermatitis (cohorts
             1-6) with a diagnostic immunoglobulin E (IgE) of 30 international units per milliliter
             (IU/mL) at Screening. Diagnostic IgE levels are further restricted for subjects
             enrolling into each cohort, with the following levels required at Screening: Cohorts 1
             and 2: 30-700 IU/mL; Cohort 3: 30-700 IU/mL (4 subjects), greater than (&gt;) 700-1,200
             IU/mL (4 subjects), and &gt;1,200 IU/mL (4 subjects); Cohort 4a: 30-500 IU/mL; Cohort 4b:
             &gt;700 IU/mL; Cohorts 5 and 6: 30-700 IU/mL (4 subjects per cohort) and &gt;700 IU/mL (6
             subjects per cohort) or Japanese Cohorts 7-9: greater than or equal to (&gt;=) 30 IU/mL

          -  Nonsmoker for &gt;=6 months

          -  Obsolete criteria as no longer require Positive in vitro IgE fluorescence enzyme
             immunoassay (FEIA) response

          -  A forced expiration volume in one second (FEV1) &gt;= 80 percent (%) predicted in
             subjects with asthma. Non-asthmatic subjects with FEV1 &gt;=80% predicted, or with FEV1
             less than (&lt;) 80% predicted but who, in the opinion of the investigator, do not have
             lung disease

          -  Ability and willingness to complete the follow-up period through Day 85 as required by
             the protocol.

        Exclusion Criteria:

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results

          -  Concurrent enrollment in another clinical study

          -  Employees of the clinical study site or any other individuals involved with the
             conduct of the study, or immediate family members of such individuals

          -  Exposure to an anti-IgE monoclonal antibodies (MAb) within 12 months prior to
             Screening

          -  Positive drug screen at Screening or Day -1. A minimum list of drugs that will be
             screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, and
             benzodiazepines

          -  History of regular alcohol abuse within 12 months prior to Screening

          -  History of sensitivity to any component of the investigational product formulation or
             a history of drug or other allergy that, in the opinion of the investigator or medical
             monitor, contraindicates their participation

          -  Subjects with abnormal liver function test values (aspartate transaminase [AST] and
             alanine transaminase [ALT]) at Screening as defined as follows: a) Liver function test
             values &gt;= 1.5 times upper limit of normal (ULN)

          -  Unwillingness or inability to follow the procedures outlined in the protocol

          -  Positive test or history of hepatitis B or positive hepatitis C

          -  Positive test or history of human immunodeficiency virus (HIV) or subject is known to
             be HIV seropositive

          -  History of cancer, with the exception of basal cell carcinoma or in situ carcinoma of
             the cervix treated with apparent success

          -  Women who are pregnant, breastfeeding, or lactating

          -  Plans to donate blood during the study period

          -  Hyper-IgE syndrome or bronchopulmonary aspergillosis

          -  Prior history of Immune Complex Disease or type 3 hypersensitivity reactions to MAb
             administration

          -  Known history of prior infusion reaction to MAb administration

          -  History of untreated parasitic/helminthic infection within 6 months prior to Screening

          -  Uses any of the following medications: a) Oral corticosteroids b) Medium to high dose
             Immunocorticosteroids (ICS)/ long-acting beta agonists (LABA) c) Immunosuppressives d)
             Beta blockers

          -  If receiving allergy immunotherapy, must be on stable dose for 3 months. Must not
             receive allergy immunotherapy within 7 days of investigational product administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2014</results_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>MEDI4212</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 295 participants were screened, out of which 209 were screen failures and 86 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Omalizumab</title>
          <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant’s Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MEDI4212 5 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MEDI4212 15 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MEDI4212 60 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>MEDI4212 150 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>MEDI4212 300 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>MEDI4212 300 mg Intravenous</title>
          <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received any amount of investigational product and had safety data available.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Omalizumab</title>
          <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant’s Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MEDI4212 5 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MEDI4212 15 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MEDI4212 60 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>MEDI4212 150 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>MEDI4212 300 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>MEDI4212 300 mg Intravenous</title>
          <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="18"/>
            <count group_id="B7" value="14"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="12.6"/>
                    <measurement group_id="B2" value="39.3" spread="9.2"/>
                    <measurement group_id="B3" value="44.7" spread="3.2"/>
                    <measurement group_id="B4" value="40.3" spread="9.6"/>
                    <measurement group_id="B5" value="38.7" spread="12.5"/>
                    <measurement group_id="B6" value="40.3" spread="11.1"/>
                    <measurement group_id="B7" value="35.9" spread="13.1"/>
                    <measurement group_id="B8" value="38.0" spread="8.6"/>
                    <measurement group_id="B9" value="39.0" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to Day 85 that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Day 1 to 85</time_frame>
        <population>Safety population included all participants who received any amount of investigational product and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab</title>
            <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant’s Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4212 5 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4212 15 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4212 60 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4212 150 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4212 300 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI4212 300 mg Intravenous</title>
            <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to Day 85 that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety population included all participants who received any amount of investigational product and had safety data available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Serum Concentration</title>
        <description>Serum concentration of omalizumab and MEDI4212 were measured for participants who received omalizumab and MEDI4212, respectively.</description>
        <time_frame>Pre-dose and post-dose on Day 1; Day 2, 3, 5, 8, 15, 22, 29, 43, 57 and 85</time_frame>
        <population>Pharmacokinetic (PK) population included all participants who received any investigational product and had a sufficient number of serum concentration measurements for computing PK parameters. Here 'n' signifies participants evaluable for this outcome measure at specified time point, for each group respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant’s Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4212 5 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4212 15 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4212 60 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4212 150 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4212 300 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4212 300 mg Intravenous</title>
            <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Concentration</title>
          <description>Serum concentration of omalizumab and MEDI4212 were measured for participants who received omalizumab and MEDI4212, respectively.</description>
          <population>Pharmacokinetic (PK) population included all participants who received any investigational product and had a sufficient number of serum concentration measurements for computing PK parameters. Here 'n' signifies participants evaluable for this outcome measure at specified time point, for each group respectively</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (predose) (n=0,1,0,0,2,1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O2" value="96.76">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O5" value="254.71" spread="134.58"/>
                    <measurement group_id="O6" value="91.69">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O7" value="158.32">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (postdose) (n=0,0,0,0,0,0,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O2" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O7" value="110693" spread="26060.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=5,1,1,12,17,13,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8941.12" spread="6361.95"/>
                    <measurement group_id="O2" value="100.36">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="292.76">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O4" value="3146.54" spread="3820.61"/>
                    <measurement group_id="O5" value="6108.21" spread="3401.45"/>
                    <measurement group_id="O6" value="14971.9" spread="9608.63"/>
                    <measurement group_id="O7" value="88457.0" spread="23398.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=5,1,1,12,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13912.4" spread="7546.50"/>
                    <measurement group_id="O2" value="110.12">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="312.73">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O4" value="3131.79" spread="2513.43"/>
                    <measurement group_id="O5" value="7969.07" spread="4004.75"/>
                    <measurement group_id="O6" value="14771" spread="8692.16"/>
                    <measurement group_id="O7" value="69776.5" spread="37738.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n=5,1,1,11,16,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17016.3" spread="6806.15"/>
                    <measurement group_id="O2" value="116.44">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="284.28">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O4" value="3336.31" spread="2759.69"/>
                    <measurement group_id="O5" value="7227.93" spread="3210.9"/>
                    <measurement group_id="O6" value="15183.4" spread="8522.98"/>
                    <measurement group_id="O7" value="34359.5" spread="6817.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=5,0,1,9,16,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16467.4" spread="5374.97"/>
                    <measurement group_id="O2" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O3" value="190.38">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O4" value="2368.21" spread="1364.28"/>
                    <measurement group_id="O5" value="7144.03" spread="5078.61"/>
                    <measurement group_id="O6" value="12611.1" spread="8382.56"/>
                    <measurement group_id="O7" value="39290.2" spread="32657.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=5,0,0,7,14,13,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15099.6" spread="5470.44"/>
                    <measurement group_id="O2" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="1134.39" spread="259.41"/>
                    <measurement group_id="O5" value="4514.83" spread="2864.46"/>
                    <measurement group_id="O6" value="8824.94" spread="6744.55"/>
                    <measurement group_id="O7" value="11391.2" spread="3673.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=5,0,0,6,12,10,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12780.2" spread="4657.23"/>
                    <measurement group_id="O2" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="521.3" spread="96.73"/>
                    <measurement group_id="O5" value="3401" spread="2140.78"/>
                    <measurement group_id="O6" value="7454.01" spread="4682.86"/>
                    <measurement group_id="O7" value="4644.04" spread="2571.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=5,0,0,4,11,8,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9466.26" spread="4040.07"/>
                    <measurement group_id="O2" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="212.22" spread="82.96"/>
                    <measurement group_id="O5" value="2176.59" spread="1390.94"/>
                    <measurement group_id="O6" value="2688.85" spread="2191.8"/>
                    <measurement group_id="O7" value="2045.55" spread="1814.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=5,2,0,0,5,5,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5195.21" spread="2263.08"/>
                    <measurement group_id="O2" value="121.39" spread="8.11"/>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O5" value="1544.4" spread="2068.43"/>
                    <measurement group_id="O6" value="1188.63" spread="949.33"/>
                    <measurement group_id="O7" value="1669.74" spread="739.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=5,2,0,0,4,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2367.85" spread="984.70"/>
                    <measurement group_id="O2" value="122.00" spread="0.35"/>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O5" value="290.44" spread="228.81"/>
                    <measurement group_id="O6" value="485.18" spread="249.73"/>
                    <measurement group_id="O7" value="150.90" spread="87.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=5,2,0,1, 3,1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="829.55" spread="434.33"/>
                    <measurement group_id="O2" value="104.07" spread="2.48"/>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="98.62">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O5" value="202.54" spread="107.75"/>
                    <measurement group_id="O6" value="84.03">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O7" value="176.87">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Exhibiting Anti-Drug Antibodies for MEDI4212 at Any Visit</title>
        <description>Anti-drug antibodies for MEDI4212 were analyzed for participants who received placebo or MEDI4212 as per planned analysis.</description>
        <time_frame>Days 1 (pre-dose), 15, 43, and 85</time_frame>
        <population>Immunogenicity population included all participants who received any investigational product and had at least one valid immunogenicity test result.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4212 5 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4212 15 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4212 60 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4212 150 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4212 300 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4212 300 mg Intravenous</title>
            <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Exhibiting Anti-Drug Antibodies for MEDI4212 at Any Visit</title>
          <description>Anti-drug antibodies for MEDI4212 were analyzed for participants who received placebo or MEDI4212 as per planned analysis.</description>
          <population>Immunogenicity population included all participants who received any investigational product and had at least one valid immunogenicity test result.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Immunoglobulin E (IgE) Serum Concentration</title>
        <time_frame>Day -28 (Screening), -1, 1 (pre-dose), 2, 3, 5, 8, 15, 22, 29, 43, 57, and 85 for all groups; 2 hours post-dose on Day 1 for MEDI4212 300 mg Intravenous group only</time_frame>
        <population>Safety population included all participants who received any amount of investigational product and had safety data available. 'n' signifies those participants who evaluable for this outcome measure at specified time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab</title>
            <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant’s Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4212 5 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4212 15 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4212 60 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4212 150 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4212 300 mg Subcutaneous</title>
            <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI4212 300 mg Intravenous</title>
            <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Immunoglobulin E (IgE) Serum Concentration</title>
          <population>Safety population included all participants who received any amount of investigational product and had safety data available. 'n' signifies those participants who evaluable for this outcome measure at specified time point for each group, respectively.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -28 (n=16,6,3,3,14,15,13,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1160.79" spread="1402.74"/>
                    <measurement group_id="O2" value="478.99" spread="369.31"/>
                    <measurement group_id="O3" value="655.76" spread="240.78"/>
                    <measurement group_id="O4" value="601.40" spread="342.13"/>
                    <measurement group_id="O5" value="2170.63" spread="3899.67"/>
                    <measurement group_id="O6" value="1976.98" spread="3172.11"/>
                    <measurement group_id="O7" value="1775.68" spread="2558.08"/>
                    <measurement group_id="O8" value="2641.68" spread="2332.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day -1 (n=17,6,3,3,15,17,14,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1025.19" spread="1287.86"/>
                    <measurement group_id="O2" value="296.73" spread="185.09"/>
                    <measurement group_id="O3" value="589.62" spread="175.14"/>
                    <measurement group_id="O4" value="522.23" spread="259.96"/>
                    <measurement group_id="O5" value="2453.85" spread="3795.64"/>
                    <measurement group_id="O6" value="1655.06" spread="2866.87"/>
                    <measurement group_id="O7" value="1681.82" spread="2161.25"/>
                    <measurement group_id="O8" value="2772.55" spread="2320.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Predose) (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1155.59" spread="1447.09"/>
                    <measurement group_id="O2" value="410.78" spread="289.39"/>
                    <measurement group_id="O3" value="552.30" spread="168.96"/>
                    <measurement group_id="O4" value="558.69" spread="305.68"/>
                    <measurement group_id="O5" value="2754.09" spread="4468.96"/>
                    <measurement group_id="O6" value="1910.45" spread="3268.58"/>
                    <measurement group_id="O7" value="1850.27" spread="2435.13"/>
                    <measurement group_id="O8" value="2426.66" spread="2460.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1:2 hours postdose (n=0,0,0,0,0,0,0,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O2" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O7" value="NA">No participant was evaluable for this outcome measure at this time point.</measurement>
                    <measurement group_id="O8" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1183.10" spread="1494.92"/>
                    <measurement group_id="O2" value="71.89" spread="157.68"/>
                    <measurement group_id="O3" value="302.31" spread="195.18"/>
                    <measurement group_id="O4" value="336.75" spread="294.36"/>
                    <measurement group_id="O5" value="1584.76" spread="3999.13"/>
                    <measurement group_id="O6" value="366.83" spread="1499.49"/>
                    <measurement group_id="O7" value="94.19" spread="351.27"/>
                    <measurement group_id="O8" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1175.50" spread="1550.93"/>
                    <measurement group_id="O2" value="74.29" spread="168.46"/>
                    <measurement group_id="O3" value="282.12" spread="179.53"/>
                    <measurement group_id="O4" value="293.78" spread="259.88"/>
                    <measurement group_id="O5" value="1366.58" spread="3496.19"/>
                    <measurement group_id="O6" value="248.20" spread="1022.97"/>
                    <measurement group_id="O7" value="42.24" spread="157.38"/>
                    <measurement group_id="O8" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1131.87" spread="1448.24"/>
                    <measurement group_id="O2" value="74.85" spread="169.36"/>
                    <measurement group_id="O3" value="297.90" spread="193.62"/>
                    <measurement group_id="O4" value="277.94" spread="240.84"/>
                    <measurement group_id="O5" value="1401.33" spread="3429.60"/>
                    <measurement group_id="O6" value="253.71" spread="1045.75"/>
                    <measurement group_id="O7" value="0.53" spread="1.43"/>
                    <measurement group_id="O8" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1119.38" spread="1417.95"/>
                    <measurement group_id="O2" value="85.00" spread="192.16"/>
                    <measurement group_id="O3" value="366.17" spread="239.65"/>
                    <measurement group_id="O4" value="288.20" spread="250.03"/>
                    <measurement group_id="O5" value="1704.44" spread="3822.59"/>
                    <measurement group_id="O6" value="362.27" spread="1408.50"/>
                    <measurement group_id="O7" value="3.17" spread="10.71"/>
                    <measurement group_id="O8" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1081.11" spread="1338.94"/>
                    <measurement group_id="O2" value="74.94" spread="161.38"/>
                    <measurement group_id="O3" value="418.27" spread="193.63"/>
                    <measurement group_id="O4" value="362.06" spread="246.96"/>
                    <measurement group_id="O5" value="2102.53" spread="4140.14"/>
                    <measurement group_id="O6" value="978.17" spread="2490.21"/>
                    <measurement group_id="O7" value="209.71" spread="539.11"/>
                    <measurement group_id="O8" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=17,6,3,3,15,17,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1084.02" spread="1294.17"/>
                    <measurement group_id="O2" value="70.95" spread="145.36"/>
                    <measurement group_id="O3" value="453.89" spread="191.07"/>
                    <measurement group_id="O4" value="406.12" spread="264.19"/>
                    <measurement group_id="O5" value="2111.36" spread="3730.60"/>
                    <measurement group_id="O6" value="1351.52" spread="2803.98"/>
                    <measurement group_id="O7" value="788.30" spread="1783.50"/>
                    <measurement group_id="O8" value="0.32" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=16,6,3,3,15,17,13,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1185.82" spread="1379.20"/>
                    <measurement group_id="O2" value="74.02" spread="143.04"/>
                    <measurement group_id="O3" value="478.53" spread="196.36"/>
                    <measurement group_id="O4" value="403.17" spread="232.44"/>
                    <measurement group_id="O5" value="2153.91" spread="3376.54"/>
                    <measurement group_id="O6" value="1676.12" spread="3296.43"/>
                    <measurement group_id="O7" value="1468.72" spread="3043.16"/>
                    <measurement group_id="O8" value="497.42" spread="628.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=16,6,3,3,15,16,13,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1089.90" spread="1306.97"/>
                    <measurement group_id="O2" value="89.32" spread="157.95"/>
                    <measurement group_id="O3" value="496.28" spread="179.01"/>
                    <measurement group_id="O4" value="510.78" spread="301.83"/>
                    <measurement group_id="O5" value="2712.59" spread="4065.37"/>
                    <measurement group_id="O6" value="1928.37" spread="3371.88"/>
                    <measurement group_id="O7" value="1912.71" spread="2966.45"/>
                    <measurement group_id="O8" value="1674.54" spread="1689.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=16,6,3,3,15,15,12,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1055.20" spread="1257.08"/>
                    <measurement group_id="O2" value="105.46" spread="159.88"/>
                    <measurement group_id="O3" value="506.63" spread="205.91"/>
                    <measurement group_id="O4" value="503.33" spread="326.80"/>
                    <measurement group_id="O5" value="2201.38" spread="3609.05"/>
                    <measurement group_id="O6" value="1394.92" spread="2394.88"/>
                    <measurement group_id="O7" value="2306.44" spread="3511.87"/>
                    <measurement group_id="O8" value="1978.31" spread="1906.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=15,6,3,3,15,16,12,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="913.17" spread="1142.25"/>
                    <measurement group_id="O2" value="294.89" spread="377.39"/>
                    <measurement group_id="O3" value="526.93" spread="227.80"/>
                    <measurement group_id="O4" value="530.49" spread="292.24"/>
                    <measurement group_id="O5" value="2014.95" spread="2952.69"/>
                    <measurement group_id="O6" value="1749.34" spread="2799.68"/>
                    <measurement group_id="O7" value="2528.85" spread="3967.57"/>
                    <measurement group_id="O8" value="2055.68" spread="1822.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to 85</time_frame>
      <desc>Safety population included all participants who received any amount of investigational product and had safety data available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Omalizumab</title>
          <description>A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant’s Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI4212 5 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MEDI4212 15 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI4212 60 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>MEDI4212 150 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>MEDI4212 300 mg Subcutaneous</title>
          <description>A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>MEDI4212 300 mg Intravenous</title>
          <description>A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Claire Birrell, Senior Clinical Scientist</name_or_title>
      <organization>MedImmune</organization>
      <phone>301-398-0000</phone>
      <email>birrellc@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

